[Progress in the treatment of hairy cell leukemia. Subcutaneous administration of 2-chloro-deoxy-adenosine for 7 days].
Hairy cell leukemia is a rare chronic B-lymphocyte malignancy characterized by pancytopenia, splenomegaly, immunological abnormalities and morphologically typical neoplastic mononuclear cells in blood and bone marrow. Until recently the disorder was treated with splenectomia and/or alpha-interferon. Intravenous infusion of 2-chloro-deoxy-adenosine (2-CdA) is a new and efficacious treatment principle making hairy cell leukemia a potentially curable disease. A Nordic cooperative study is currently examining the effects of 2-CdA given subcutaneously for seven days. 19 Norwegian patients are included so far, with encouraging results. The long-term effect of 2-CdA is not yet known. The high remission frequency, the short duration of the treatment and the few side effects make this drug a natural first choice in treating hairy cell leukemia.
Heldal
D
D
Hematologisk seksjon, Medisinsk avdeling A, Rikshospitalet, Oslo.
Tjønnfjord
G E
GE
Evensen
S A
SA
Juliusson
G
G
D000328:Adult; D000368:Aged; D017338:Cladribine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013997:Time Factors
D017338:Cladribine
Fremskritt i behandlingen av hårcelleleukemi. 2-kloro-deoksy-adenosin (2-CdA) gitt subkutant i sju dager.